search
Back to results

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Primary Purpose

Leukemia

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Bendamustine
Sponsored by
Teva Branded Pharmaceutical Products R&D, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia

Eligibility Criteria

1 Year - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • The patient has histologically proven acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML) that has relapsed or is refractory to the last regimen, and the patient is without alternative curative therapy.
  • The patient's last myelosuppression therapy ended at least 2 weeks before the first dose of study drug.
  • Nonhematologic acute toxic effects of prior therapy have resolved to grade 2 or less according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
  • The patient has adequate liver function with bilirubin values less than or equal to 1.5 times the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values less than or equal to 5 times the age-appropriate ULN.
  • The patient has adequate renal function with serum creatinine values less than 2 times ULN.
  • The patient has Karnofsky or Lansky performance status of 60 or greater. Patients older than 16 years of age will be scored according to the Karnofsky scale and patients 16 years of age or younger will be scored according to the Lansky scale.
  • The patient may have had hematopoietic stem cell transplantation.
  • Women of childbearing potential (not surgically sterile) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment.
  • Men not surgically sterile or who are capable of producing offspring must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment.
  • The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.

Key Exclusion Criteria:

  • The patient has any active, uncontrolled systemic infection, severe concurrent disease, or symptomatic untreated central nervous system (CNS) involvement.
  • The patient has evidence of active graft versus host disease.
  • The patient has a known human immunodeficiency virus (HIV) infection.
  • The patient has active hepatitis B or hepatitis C infection.
  • The patient is a pregnant or lactating woman. Any women becoming pregnant during the study will be withdrawn from the study immediately.
  • The patient has any serious uncontrolled medical or psychological disorder that would impair the ability of the patient to receive study drug.
  • The patient has any condition that places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data.
  • The patient has received any other investigational agent within 30 days of study entry.
  • The patient has known hypersensitivity to bendamustine or mannitol.

Sites / Locations

  • Teva Investigational Site 17
  • Teva Investigational Site 12
  • Teva Investigational Site 10
  • Teva Investigational Site 8
  • Teva Investigational Site 16
  • Teva Investigational Site 9
  • Teva Investigational Site 1
  • Teva Investigational Site 5
  • Teva Investigational Site 14
  • Teva Investigational Site 15
  • Teva Investigational Site 18
  • Teva Investigational Site 11
  • Teva Investigational Site 7
  • Teva Investigational Site 19
  • Teva Investigational Site 3
  • Teva Investigational Site 4
  • Teva Investigational Site 13
  • Teva Investigational Site 2
  • Teva Investigational Site 6
  • Teva Investigational Site 300
  • Teva Investigational Site 301
  • Teva Investigational Site 302
  • Teva Investigational Site 520
  • Teva Investigational Site 615
  • Teva Investigational Site 616
  • Teva Investigational Site 613
  • Teva Investigational Site 612
  • Teva Investigational Site 614
  • Teva Investigational Site 617
  • Teva Investigational Site 610
  • Teva Investigational Site 611
  • Teva Investigational Site 100
  • Teva Investigational Site 501
  • Teva Investigational Site 503
  • Teva Investigational Site 502
  • Teva Investigational Site 330
  • Teva Investigational Site 331
  • Teva Investigational Site 332
  • Teva Investigational Site 333
  • Teva Investigational Site 603
  • Teva Investigational Site 600
  • Teva Investigational Site 601
  • Teva Investigational Site 602
  • Teva Investigational Site 303
  • Teva Investigational Site 531
  • Teva Investigational Site 530
  • Teva Investigational Site 532
  • Teva Investigational Site 511
  • Teva Investigational Site 510
  • Teva Investigational Site 320

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bendamustine

Arm Description

Bendamustine 90 or 120 mg/m^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.

Outcomes

Primary Outcome Measures

Recommended Phase II Dose (RP2D) of Bendamustine
RP2D was determined by a traditional 3+3 dose escalation design, with the following restrictions: only doses of 60, 90, 120, and 150 mg/m^2 were explored, and escalation to 150 mg/m^2 would only occur if the 120 mg/m^2 dose was deemed safe and pharmacokinetic data indicate subtherapeutic exposure as compared with adults. The first cohort was administered bendamustine at the 90 mg/m^2 dose; de-escalation to the 60 mg/m^2 dose would only occur if the starting dose led to dose-limiting toxicity (DLT) in 2 or more participants. A DLT was defined as any study drug-related nonhematologic adverse event (AE) that was grade 4 for toxicity by National Cancer Institute's Common Toxicity Criteria for AEs, version 4. In addition, grade 3 or above allergic reaction or skin rash were considered DLTs. Hematologic AEs were not considered DLTs. The dose level at which at least 2 of 3 or 2 of 6 participants had a DLT was considered as exceeding the RP2D. The RP2D was the dose 1 step below that level.
Overall Response Rate (ORR)
ORR was calculated as follows: number of participants in the primary analysis set achieving a best overall response of complete remission without platelet recovery (CRp) or complete remission (CR), divided by the number of participants in the primary analysis set. The most positive response for each patient during the study was counted. The 95% CI was calculated using binomial parameter exact method. Response was determined by the investigator, and evaluated per Jeha et al, 2006: A CR required no evidence of circulating blasts or extramedullary disease, an M1 marrow (≤ 5% bone marrow blasts), and recovery of peripheral counts (platelets ≥ 100 × 10^9/L and absolute neutrophil count ≥ 1.0 × 10^9/L). A CR without platelet recovery (CRp) required all of the criteria for a CR with the exception of platelet recovery.

Secondary Outcome Measures

Best Overall Tumor Response Rate
Biological activity of bendamustine was defined as achieving a best response of partial response (PR), CRp, or CR. Rate was calculated as follows: number of participants in the primary analysis set achieving a best overall response of PR, CRp, or CR, divided by the number of participants in the primary analysis set. The most positive response for each patient during the study was counted. The 95% CI was calculated using binomial parameter exact method. Response was determined by the investigator, and evaluated per Jeha et al, 2006: A PR had to meet the following criteria: complete disappearance of circulating blasts and an M2 marrow (≥ 5% and ≤ 25% bone marrow blasts) and appearance of normal progenitor cells or an M1 marrow that did not qualify for CR or CRp. See Outcome Measure 2 for full definitions for CRp and CR.
Best Overall Tumor Response Rate, by Phase
Biological activity of bendamustine was defined as achieving a best response of partial response (PR), CRp, or CR. Rate was calculated as follows: number of participants in the primary analysis set achieving a best overall response of PR, CRp, or CR, divided by the number of participants in the primary analysis set. The most positive response for each patient during the study was counted. The 95% CI was calculated using binomial parameter exact method. Response was determined by the investigator, and evaluated per Jeha et al, 2006: A PR had to meet the following criteria: complete disappearance of circulating blasts and an M2 marrow (≥ 5% and ≤ 25% bone marrow blasts) and appearance of normal progenitor cells or an M1 marrow that did not qualify for CR or CRp. See Outcome Measure 2 for full definitions for CRp and CR.
Duration of Response (DOR)
DOR was determined for the participants with CR or CRp in the primary analysis set, defined as the time from first achieving remission to the time when progression was diagnosed, the participant died, or the participant started receiving new antineoplastic therapy. Data from participants who do not progress were censored at the last valid assessments. Median DOR and its 95% confidence interval was determined based on the Kaplan-Meier method. Data from participants who received a transplant were censored at the time of the transplant.
Maximum Observed Plasma Drug Concentration (Cmax) for Bendamustine and Its Metabolites (M3 and M4)
Time to Maximum Plasma Drug Concentration (Tmax) for Bendamustine and Its Metabolites (M3 and M4)
Area Under the Plasma Drug Concentration by Time Curve From Time 0 Until the Last Measurable Plasma Concentration (AUC0-t) for Bendamustine and Its Metabolites (M3 and M4)
Area Under the Plasma Drug Concentration by Time Curve From Time 0 Until 24 Hours After Study Drug Administration (AUC0-24) for Bendamustine and Its Metabolites (M3 and M4)

Full Information

First Posted
March 16, 2010
Last Updated
April 21, 2016
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01088984
Brief Title
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Official Title
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.

4. Oversight

5. Study Description

Brief Summary
The primary objective of phase 1 of this study is to establish the recommended phase II dose (RP2D). The primary objective of phase 2 of this study is to evaluate the safety and efficacy of bendamustine at the recommended pediatric dose for the treatment of pediatric patients with relapsed or refractory acute leukemia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bendamustine
Arm Type
Experimental
Arm Description
Bendamustine 90 or 120 mg/m^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.
Intervention Type
Drug
Intervention Name(s)
Bendamustine
Primary Outcome Measure Information:
Title
Recommended Phase II Dose (RP2D) of Bendamustine
Description
RP2D was determined by a traditional 3+3 dose escalation design, with the following restrictions: only doses of 60, 90, 120, and 150 mg/m^2 were explored, and escalation to 150 mg/m^2 would only occur if the 120 mg/m^2 dose was deemed safe and pharmacokinetic data indicate subtherapeutic exposure as compared with adults. The first cohort was administered bendamustine at the 90 mg/m^2 dose; de-escalation to the 60 mg/m^2 dose would only occur if the starting dose led to dose-limiting toxicity (DLT) in 2 or more participants. A DLT was defined as any study drug-related nonhematologic adverse event (AE) that was grade 4 for toxicity by National Cancer Institute's Common Toxicity Criteria for AEs, version 4. In addition, grade 3 or above allergic reaction or skin rash were considered DLTs. Hematologic AEs were not considered DLTs. The dose level at which at least 2 of 3 or 2 of 6 participants had a DLT was considered as exceeding the RP2D. The RP2D was the dose 1 step below that level.
Time Frame
Induction Cycle (21- to 35-day cycle)
Title
Overall Response Rate (ORR)
Description
ORR was calculated as follows: number of participants in the primary analysis set achieving a best overall response of complete remission without platelet recovery (CRp) or complete remission (CR), divided by the number of participants in the primary analysis set. The most positive response for each patient during the study was counted. The 95% CI was calculated using binomial parameter exact method. Response was determined by the investigator, and evaluated per Jeha et al, 2006: A CR required no evidence of circulating blasts or extramedullary disease, an M1 marrow (≤ 5% bone marrow blasts), and recovery of peripheral counts (platelets ≥ 100 × 10^9/L and absolute neutrophil count ≥ 1.0 × 10^9/L). A CR without platelet recovery (CRp) required all of the criteria for a CR with the exception of platelet recovery.
Time Frame
Assessed at each treatment cycle (21 to 35 days), for a maximum of 12 cycles
Secondary Outcome Measure Information:
Title
Best Overall Tumor Response Rate
Description
Biological activity of bendamustine was defined as achieving a best response of partial response (PR), CRp, or CR. Rate was calculated as follows: number of participants in the primary analysis set achieving a best overall response of PR, CRp, or CR, divided by the number of participants in the primary analysis set. The most positive response for each patient during the study was counted. The 95% CI was calculated using binomial parameter exact method. Response was determined by the investigator, and evaluated per Jeha et al, 2006: A PR had to meet the following criteria: complete disappearance of circulating blasts and an M2 marrow (≥ 5% and ≤ 25% bone marrow blasts) and appearance of normal progenitor cells or an M1 marrow that did not qualify for CR or CRp. See Outcome Measure 2 for full definitions for CRp and CR.
Time Frame
At each treatment cycle (21 to 35 days), for a maximum of 12 cycles
Title
Best Overall Tumor Response Rate, by Phase
Description
Biological activity of bendamustine was defined as achieving a best response of partial response (PR), CRp, or CR. Rate was calculated as follows: number of participants in the primary analysis set achieving a best overall response of PR, CRp, or CR, divided by the number of participants in the primary analysis set. The most positive response for each patient during the study was counted. The 95% CI was calculated using binomial parameter exact method. Response was determined by the investigator, and evaluated per Jeha et al, 2006: A PR had to meet the following criteria: complete disappearance of circulating blasts and an M2 marrow (≥ 5% and ≤ 25% bone marrow blasts) and appearance of normal progenitor cells or an M1 marrow that did not qualify for CR or CRp. See Outcome Measure 2 for full definitions for CRp and CR.
Time Frame
At each treatment cycle (21 to 35 days), for a maximum of 12 cycles
Title
Duration of Response (DOR)
Description
DOR was determined for the participants with CR or CRp in the primary analysis set, defined as the time from first achieving remission to the time when progression was diagnosed, the participant died, or the participant started receiving new antineoplastic therapy. Data from participants who do not progress were censored at the last valid assessments. Median DOR and its 95% confidence interval was determined based on the Kaplan-Meier method. Data from participants who received a transplant were censored at the time of the transplant.
Time Frame
At each treatment cycle (21 to 35 days), for a maximum of 12 cycles
Title
Maximum Observed Plasma Drug Concentration (Cmax) for Bendamustine and Its Metabolites (M3 and M4)
Time Frame
Cycle 1, Day 1: before infusion, immediately following the infusion, and 3, 6, 10(±2), and 24 hours after the start of infusion. The 24-hour postinfusion sample was obtained before the start of the infusion on Day 2.
Title
Time to Maximum Plasma Drug Concentration (Tmax) for Bendamustine and Its Metabolites (M3 and M4)
Time Frame
Cycle 1, Day 1: before infusion, immediately following the infusion, and 3, 6, 10(±2), and 24 hours after the start of infusion. The 24-hour postinfusion sample was obtained before the start of the infusion on Day 2.
Title
Area Under the Plasma Drug Concentration by Time Curve From Time 0 Until the Last Measurable Plasma Concentration (AUC0-t) for Bendamustine and Its Metabolites (M3 and M4)
Time Frame
Cycle 1, Day 1: before infusion, immediately following the infusion, and 3, 6, 10(±2), and 24 hours after the start of infusion. The 24-hour postinfusion sample was obtained before the start of the infusion on Day 2.
Title
Area Under the Plasma Drug Concentration by Time Curve From Time 0 Until 24 Hours After Study Drug Administration (AUC0-24) for Bendamustine and Its Metabolites (M3 and M4)
Time Frame
Cycle 1, Day 1: before infusion, immediately following the infusion, and 3, 6, 10(±2), and 24 hours after the start of infusion. The 24-hour postinfusion sample was obtained before the start of the infusion on Day 2.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: The patient has histologically proven acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML) that has relapsed or is refractory to the last regimen, and the patient is without alternative curative therapy. The patient's last myelosuppression therapy ended at least 2 weeks before the first dose of study drug. Nonhematologic acute toxic effects of prior therapy have resolved to grade 2 or less according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). The patient has adequate liver function with bilirubin values less than or equal to 1.5 times the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values less than or equal to 5 times the age-appropriate ULN. The patient has adequate renal function with serum creatinine values less than 2 times ULN. The patient has Karnofsky or Lansky performance status of 60 or greater. Patients older than 16 years of age will be scored according to the Karnofsky scale and patients 16 years of age or younger will be scored according to the Lansky scale. The patient may have had hematopoietic stem cell transplantation. Women of childbearing potential (not surgically sterile) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment. Men not surgically sterile or who are capable of producing offspring must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment. The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol. Key Exclusion Criteria: The patient has any active, uncontrolled systemic infection, severe concurrent disease, or symptomatic untreated central nervous system (CNS) involvement. The patient has evidence of active graft versus host disease. The patient has a known human immunodeficiency virus (HIV) infection. The patient has active hepatitis B or hepatitis C infection. The patient is a pregnant or lactating woman. Any women becoming pregnant during the study will be withdrawn from the study immediately. The patient has any serious uncontrolled medical or psychological disorder that would impair the ability of the patient to receive study drug. The patient has any condition that places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data. The patient has received any other investigational agent within 30 days of study entry. The patient has known hypersensitivity to bendamustine or mannitol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sponsor's Medical Expert
Organizational Affiliation
Cephalon
Official's Role
Study Director
Facility Information:
Facility Name
Teva Investigational Site 17
City
Orange
State/Province
California
Country
United States
Facility Name
Teva Investigational Site 12
City
San Diego
State/Province
California
Country
United States
Facility Name
Teva Investigational Site 10
City
St. Petersburg
State/Province
Florida
Country
United States
Facility Name
Teva Investigational Site 8
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Teva Investigational Site 16
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
Teva Investigational Site 9
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
Teva Investigational Site 1
City
Jackson
State/Province
Mississippi
Country
United States
Facility Name
Teva Investigational Site 5
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
Teva Investigational Site 14
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
Teva Investigational Site 15
City
New York
State/Province
New York
Country
United States
Facility Name
Teva Investigational Site 18
City
Portland
State/Province
Oregon
Country
United States
Facility Name
Teva Investigational Site 11
City
Hershey
State/Province
Pennsylvania
Country
United States
Facility Name
Teva Investigational Site 7
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
Teva Investigational Site 19
City
Memphis
State/Province
Tennessee
Country
United States
Facility Name
Teva Investigational Site 3
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Teva Investigational Site 4
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
Teva Investigational Site 13
City
Houston
State/Province
Texas
Country
United States
Facility Name
Teva Investigational Site 2
City
Seattle
State/Province
Washington
Country
United States
Facility Name
Teva Investigational Site 6
City
Milwaukee
State/Province
Wisconsin
Country
United States
Facility Name
Teva Investigational Site 300
City
Herston
Country
Australia
Facility Name
Teva Investigational Site 301
City
Parkville
Country
Australia
Facility Name
Teva Investigational Site 302
City
Randwick
Country
Australia
Facility Name
Teva Investigational Site 520
City
Minsk
Country
Belarus
Facility Name
Teva Investigational Site 615
City
Barretos-SP
Country
Brazil
Facility Name
Teva Investigational Site 616
City
Caxias do Sul
Country
Brazil
Facility Name
Teva Investigational Site 613
City
Curitiba-PR
Country
Brazil
Facility Name
Teva Investigational Site 612
City
Porto Alegre
Country
Brazil
Facility Name
Teva Investigational Site 614
City
Porto Alegre
Country
Brazil
Facility Name
Teva Investigational Site 617
City
Sao Paulo-SP
Country
Brazil
Facility Name
Teva Investigational Site 610
City
Sao Paulo
Country
Brazil
Facility Name
Teva Investigational Site 611
City
Sao Paulo
Country
Brazil
Facility Name
Teva Investigational Site 100
City
Toronto
Country
Canada
Facility Name
Teva Investigational Site 501
City
Jerusalem
Country
Israel
Facility Name
Teva Investigational Site 503
City
Petach Tikva
Country
Israel
Facility Name
Teva Investigational Site 502
City
Ramat Gan
Country
Israel
Facility Name
Teva Investigational Site 330
City
Seoul
Country
Korea, Republic of
Facility Name
Teva Investigational Site 331
City
Seoul
Country
Korea, Republic of
Facility Name
Teva Investigational Site 332
City
Seoul
Country
Korea, Republic of
Facility Name
Teva Investigational Site 333
City
Seoul
Country
Korea, Republic of
Facility Name
Teva Investigational Site 603
City
Guadalajara
Country
Mexico
Facility Name
Teva Investigational Site 600
City
Mexico City
Country
Mexico
Facility Name
Teva Investigational Site 601
City
Mexico City
Country
Mexico
Facility Name
Teva Investigational Site 602
City
Monterrey
Country
Mexico
Facility Name
Teva Investigational Site 303
City
Auckland
Country
New Zealand
Facility Name
Teva Investigational Site 531
City
Bialystok
Country
Poland
Facility Name
Teva Investigational Site 530
City
Lublin
Country
Poland
Facility Name
Teva Investigational Site 532
City
Warszawa
Country
Poland
Facility Name
Teva Investigational Site 511
City
Moscow
Country
Russian Federation
Facility Name
Teva Investigational Site 510
City
St. Petersburg
Country
Russian Federation
Facility Name
Teva Investigational Site 320
City
Singapore
Country
Singapore

12. IPD Sharing Statement

Citations:
PubMed Identifier
24072240
Citation
Fraser C, Brown P, Megason G, Ahn HS, Cho B, Kirov I, Frankel L, Aplenc R, Bensen-Kennedy D, Munteanu M, Weaver J, Harker-Murray P. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability. J Pediatr Hematol Oncol. 2014 May;36(4):e212-8. doi: 10.1097/MPH.0000000000000021.
Results Reference
background

Learn more about this trial

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

We'll reach out to this number within 24 hrs